Modified lipase and its use

By mutation of the specific amino acid sequence of Candida lipase columnar, the modified lipase was generated, which solved the problem of insufficient stability and reactivity at high temperatures, and significantly improved the application value at high temperatures.

CN111032872BActive Publication Date: 2024-11-22AMANO ENZYME INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880055881.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-09-01
Filing Date
2018-08-17
Publication Date
2024-11-22
Estimated Expiration
2038-08-17

AI Technical Summary

Technical Problem

The lack of stability and reactivity of lipase derived from Candida columnaria at high temperatures limits its productivity and use in industrial applications.

Method used

Modified lipase is generated by performing specific mutations on the amino acid sequence of Candida lipase, such as the substitution of T130C-S153C, A249P, F259Y, S282P, S283Y and S300P, and its reactivity and stability at high temperatures are improved.

Benefits of technology

The relative activity and activity residual rate of modified lipase at high temperatures has been significantly improved, which has greatly improved its application value under high temperature conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0002393753680000011
    Figure HDA0002393753680000011
  • Figure HDA0002393753680000012
    Figure HDA0002393753680000012
Patent Text Reader

Abstract

The present invention aims to provide a modified lipase having excellent stability and reactivity at high temperatures. A modified lipase having an amino acid sequence containing one or more amino acid substitutions selected from T130C-S153C, A249P, F259Y, S282P, S283Y and S300P in the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence showing 90% or more homology with the amino acid sequence, wherein the reactivity and / or stability at high temperatures are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a modified lipase. Specifically, the present invention provides a modified lipase having improved reactivity and / or stability at high temperature and its use. This application claims priority based on Japanese Patent Application No. 2017-168995 filed on September 1, 2017, the entire contents of which are incorporated herein by reference. Background Art

[0002] Lipase is an enzyme that acts on the ester bonds in lipids. Lipases from various sources are isolated and used for the decomposition of fats and oils, food processing, and the manufacture of pharmaceuticals. For example, lipase from Candida cylindracea (formerly known as lipase from Candida rugosa) is expected to be used in the fields of wastewater treatment and food processing (see, for example, Patent Documents 1 to 3 and Non-Patent Document 1).

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: International Publication No. 2012 / 077614 Pamphlet

[0006] Patent Document 2: Japanese Patent Application Publication No. 2017-73980

[0007] Patent Document 3: Japanese Patent Application Publication No. 2003-144162

[0008] Non-patent literature

[0009] Non-patent document 1: Akai Shuichi, Research on the development of asymmetric synthesis reactions aiming at next-generation enzyme-catalyzed reactions, YAKUGAKU ZASSHI, Vol. 123 (2003) No. 11. P919-931. Summary of the invention

[0010] The lipase from Candida columnaris is highly useful in industry. However, the stability and reactivity of the lipase at high temperature can be improved. If the stability / reactivity at high temperature is improved, the productivity can be improved and the application can be expanded. Therefore, the subject of the present invention is to improve the stability / reactivity at high temperature of the lipase from Candida columnaris, and to improve its usefulness and utilization value.

[0011] In order to solve the above problems, the present inventors tried to modify the lipase derived from Candida columnaris. After repeated experiments, they successfully determined the mutation point (amino acid residue) that is effective for improving the reactivity or stability at high temperature, and obtained a highly useful mutant (modified lipase). This achievement is also important in providing information and means for designing and obtaining mutants that can achieve the purpose of improving reactivity and stability at high temperature.

[0012] However, there is a lot of experience that there is a high probability of producing an additive or synergistic effect by combining two effective mutations. In addition, given the technical common sense that the structures (primary structure, three-dimensional structure) of the same enzymes are highly similar and the same mutations are likely to produce the same effect, if the useful mutations found in the lipase derived from Candida columnaris having the amino acid sequence of SEQ ID NO: 1 are applied to other lipases that have a high structural similarity to the lipase, there is a high probability that the same effect will be produced, and those skilled in the art will recognize that such application is effective.

[0013] The following invention is based on the above results and considerations.

[0014] [1] A modified lipase having an amino acid sequence in which one or more amino acids selected from T130C-S153C, A249P, F259Y, S282P, S283Y and S300P are substituted in the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence showing 90% or more homology with the amino acid sequence, wherein the modified lipase has improved reactivity and / or stability at high temperatures compared to the lipase consisting of the amino acid sequence of SEQ ID NO: 1.

[0015] [2] The modified lipase according to [1], wherein the amino acid substitution contained in the amino acid sequence of the modified lipase is T130C-S153C or S283Y, and the reactivity at high temperature is improved.

[0016] [3] The modified lipase according to [1], wherein the amino acid substitution contained in the amino acid sequence of the modified lipase is A249P, S283Y or S300P, and the stability at high temperature is improved.

[0017] [4] A lipase comprising any one of the amino acid sequences of SEQ ID NOs: 2 to 7 or an amino acid sequence showing 90% or more homology to the amino acid sequence (wherein, when the basis of homology is the amino acid sequence of SEQ ID NO: 2, the amino acid sequence differs at positions other than cysteine ​​at position 130 and cysteine ​​at position 153; when the basis of homology is the amino acid sequence of SEQ ID NO: 3, the amino acid sequence differs at positions other than proline at position 249; when the basis of homology is the amino acid sequence of SEQ ID NO: 4, the amino acid sequence differs at positions other than tyrosine at position 259; when the basis of homology is the amino acid sequence of SEQ ID NO: 5, the amino acid sequence differs at positions other than proline at position 282; when the basis of homology is the amino acid sequence of SEQ ID NO: 6, the amino acid sequence differs at positions other than tyrosine at position 283; and when the basis of homology is the amino acid sequence of SEQ ID NO: 7, the amino acid sequence differs at positions other than proline at position 300), wherein the lipase has improved reactivity and / or stability at high temperatures compared to the lipase consisting of the amino acid sequence of SEQ ID NO: 1.

[0018] [5] A gene encoding the modified lipase according to any one of [1] to [4].

[0019] [6] The gene according to [5], comprising any one of the base sequences of SEQ ID NOs: 8 to 19.

[0020] [7] A recombinant DNA comprising the gene described in [5] or [6].

[0021] [8] A microorganism that possesses the recombinant DNA described in [7].

[0022] [9] The microorganism according to [8], wherein the host is Escherichia coli, Candida columnaris, Aspergillus oryzae, Bacillus subtilis or Pichia pastoris.

[0023]

[10] An enzyme preparation comprising the modified lipase according to any one of [1] to [4].

[0024]

[11] A method for decomposing fats and oils, characterized in that the enzyme described in any one of [1] to [4] or the enzyme preparation described in

[10] is allowed to act on the fats and oils to carry out an enzyme reaction.

[0025]

[12] The decomposition method according to

[11] , wherein the enzyme reaction is carried out at 30°C to 70°C.

[0026]

[13] A method for preparing a modified lipase, comprising the following steps (I) to (III):

[0027] (I) preparing a nucleic acid encoding any one of the amino acid sequences of SEQ ID NOs: 2 to 7;

[0028] (II) a step of expressing the above nucleic acid, and

[0029] (III) A step of recovering the expression product. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 is the reactivity of the mutant at high temperature. The relative activity (ratio of enzyme activity at 60°C to enzyme activity at 30°C) was compared with that of the wild-type enzyme.

[0031] Figure 2 The activity residual rate after treatment at 50°C for 30 minutes was compared with that of the wild-type enzyme. DETAILED DESCRIPTION

[0032] For the purpose of explanation, some of the terms used in connection with the present invention are defined below.

[0033] (the term)

[0034] The term "modified lipase" refers to an enzyme obtained by modifying or mutating a benchmark lipase (hereinafter referred to as "benchmark lipase"). Typically, the benchmark lipase is a lipase from Candida cylindracea having an amino acid sequence of SEQ ID NO: 1. The term "lipase from Candida cylindracea" and the term "lipase from Candida rugosa" can be used interchangeably.

[0035] The term "lipase derived from Candida columnaris" refers to a lipase originating from Candida columnaris, and includes a lipase produced by Candida columnaris or a lipase expressed by other microorganisms etc. using the genetic information of the lipase.

[0036] In the present invention, "amino acid substitution" is performed as modification or mutation. Therefore, if the modified lipase is compared with the reference lipase, some amino acid residues are found to be different. It should be noted that in this specification, the modified lipase is also referred to as a modified enzyme or a mutant.

[0037] In this specification, according to convention, each amino acid is represented by a single letter as shown below.

[0038] Methionine: M, Serine: S, Alanine: A, Threonine: T, Valine: V, Tyrosine: Y, Leucine: L, Asparagine: N, Isoleucine: I, Glutamine: Q, Proline: P, Aspartic acid: D, Phenylalanine: F, Glutamic acid: E, Tryptophan: W, Lysine: K, Cysteine: C, Arginine: R, Glycine: G, Histidine: H

[0039] In the present specification, the amino acid residue at the N-terminus of the mature form in which the signal peptide is cleaved is designated as the first position, and the positions of mutation points are identified by the accompanying numbers from the N-terminus toward the C-terminus.

[0040] In this specification, the amino acid residue at the mutation point (the amino acid residue to be substituted) is expressed by a combination of the above-mentioned single letter indicating the type of amino acid and a number indicating the amino acid position. For example, a mutation in which threonine at position 130 is substituted with cysteine ​​is expressed as "T130C".

[0041] 1. Modified lipase

[0042] The first aspect of the present invention relates to a modified lipase (modified enzyme). Typically, the modified enzyme of the present invention has an amino acid sequence containing one or more amino acid substitutions selected from T130C-S153C, A249P, F259Y, S282P, S283Y and S300P in the amino acid sequence of sequence number 1. According to this feature, compared with the lipase consisting of the amino acid sequence of sequence number 1, the reactivity at high temperature or the stability at high temperature is improved or both are improved. It should be noted that the amino acid sequence of sequence number 1 is the sequence of the mature body (i.e., not including a signal peptide) of the lipase from Candida columnaris (referred to as "LIP1" in the present application specification).

[0043] In order to facilitate understanding, judgment, and determination of the high temperature reactivity and high temperature stability of the modified enzyme, the high temperature for high temperature reactivity is "55°C to 65°C", and the high temperature for high temperature stability is "45°C to 55°C".

[0044] High temperature reactivity can be evaluated, for example, based on the ratio of the enzyme activity at 60°C to the enzyme activity at 30°C (relative activity at 60°C based on the activity at 30°C). The modified enzyme has improved high temperature reactivity compared to the benchmark lipase (i.e., the lipase consisting of the amino acid sequence of sequence number 1), so its relative activity is higher than the benchmark lipase. The relative activity of the modified enzyme is, for example, 1.5 to 10 times the relative activity of the benchmark lipase. Preferably, it is 3 to 10 times. It should be noted that the relative activity is calculated as follows.

[0045] Relative activity = (enzyme activity at 60°C / enzyme activity at 30°C) × 100 (%)

[0046] On the other hand, high temperature stability can be evaluated based on the residual activity when treated at 50°C for 30 minutes, for example. The high temperature stability of the modified enzyme is improved compared to the benchmark lipase (i.e., the lipase consisting of the amino acid sequence of sequence number 1), so its activity residual rate is higher than the benchmark lipase. The activity residual rate of the modified enzyme is, for example, 1.1 to 2.0 times the activity residual rate of the benchmark lipase. Preferably, it is 1.5 to 2.0 times. It should be noted that the activity residual rate is calculated as follows.

[0047] Remaining activity rate = (enzyme activity after heat treatment / enzyme activity before heat treatment) × 100 (%)

[0048] In this specification, "containing amino acid substitution" means that the mutation point (i.e., the position of the amino acid residue producing a specific amino acid substitution) becomes the substituted amino acid. Therefore, if the amino acid sequence containing amino acid substitution (mutant amino acid sequence) is compared with the amino acid sequence of sequence number 1 not containing amino acid substitution (reference amino acid sequence), there is a difference in the amino acid residue at the position of the amino acid substitution.

[0049] T130C-S153C represents a mutation in which the amino acid at position 130 (threonine) of the amino acid sequence of sequence number 1 is replaced by cysteine, and the amino acid at position 153 (serine) is replaced by cysteine. A249P represents a mutation in which the amino acid at position 249 (alanine) of the amino acid sequence of sequence number 1 is replaced by proline. F259Y represents a mutation in which the amino acid at position 259 (phenylalanine) of the amino acid sequence of sequence number 1 is replaced by tyrosine. S282P represents a mutation in which the amino acid at position 282 (serine) of the amino acid sequence of sequence number 1 is replaced by proline. S283Y represents a mutation in which the amino acid at position 283 (serine) of the amino acid sequence of sequence number 1 is replaced by tyrosine. S300P represents a mutation in which the amino acid at position 300 (serine) of the amino acid sequence of sequence number 1 is replaced by proline.

[0050] As a specific example of the modified enzyme of the present invention, a lipase consisting of any one of the amino acid sequences of sequence numbers 2 to 7 can be cited (corresponding to mutant 1 (T130C-S153C), mutant 2 (A249P), mutant 3 (F259Y), mutant 4 (S282P), mutant 5 (S283Y), mutant 6 (S300P) in that order). As shown in the examples described below, it can be confirmed that the lipase consisting of the amino acid sequence of sequence number 2 (mutant 1 (T130C-S153C)) and the lipase consisting of the amino acid sequence of sequence number 6 (mutant 5 (S283Y)) have particularly high reactivity at high temperatures. On the other hand, it can be confirmed that the lipase composed of the amino acid sequence of sequence number 3 (mutant 2 (A249P)), the lipase composed of the amino acid sequence of sequence number 6 (mutant 5 (S283Y)), and the lipase composed of the amino acid sequence of sequence number 7 (mutant 6 (S300P)) have particularly high stability at high temperatures.

[0051] In general, when a part of the amino acid sequence of a certain protein is mutated, sometimes the mutated protein has the same function as the protein before the mutation. That is, sometimes the mutation of the amino acid sequence does not substantially affect the function of the protein, and the function of the protein is maintained before and after the mutation. On the other hand, when the homology of the amino acid sequences of two proteins is high, the probability of both showing the same characteristics is high. If these technical common sense are taken into account, it is not completely the same (i.e., 100% homology) as the amino acid sequence of the above-mentioned modified enzyme, i.e., "the amino acid sequence of sequence number 1 contains one or more amino acid substitutions selected from T130C-S153C, A249P, F259Y, S282P, S283Y and S300P (the specific example of the amino acid sequence is the amino acid sequence of sequence numbers 2 to 7)", but it shows an amino acid sequence with high homology, and if the reactivity and / or stability at high temperature are improved, it can be regarded as an enzyme substantially the same as the above-mentioned modified enzyme (substantially homologous lipase). The homology here is preferably 90% or more, more preferably 95% or more, further preferably 98% or more, and most preferably 99% or more. If the above-mentioned modified enzyme is compared with a substantially homologous lipase, it is found that the amino acid sequence is slightly different. Among them, the difference in amino acid sequence occurs at positions other than the positions where the above-mentioned amino acid substitution is performed. Therefore, when the basis of homology is the amino acid sequence of sequence number 2, the difference in amino acid sequence occurs at positions other than cysteine ​​at position 130 and cysteine ​​at position 153, when the basis of homology is the amino acid sequence of sequence number 3, the difference in amino acid sequence occurs at positions other than proline at position 249, when the basis of homology is the amino acid sequence of sequence number 4, the difference in amino acid sequence occurs at positions other than tyrosine at position 259, when the basis of homology is the amino acid sequence of sequence number 5, the difference in amino acid sequence occurs at positions other than proline at position 282, when the basis of homology is the amino acid sequence of sequence number 6, the difference in amino acid sequence occurs at positions other than tyrosine at position 283, and when the basis of homology is the amino acid sequence of sequence number 7, the difference in amino acid sequence occurs at positions other than proline at position 300. In other words, in the amino acid sequence showing 90% or more homology with the amino acid sequence of SEQ ID NO: 2, both the amino acid at position 130 and the amino acid at position 153 are cysteine.Similarly, in the amino acid sequence showing more than 90% homology with the amino acid sequence of sequence number 3, the amino acid at position 249 is proline, in the amino acid sequence showing more than 90% homology with the amino acid sequence of sequence number 4, the amino acid at position 259 is tyrosine, in the amino acid sequence showing more than 90% homology with the amino acid sequence of sequence number 5, the amino acid at position 282 is proline, in the amino acid sequence showing more than 90% homology with the amino acid sequence of sequence number 6, the amino acid at position 283 is tyrosine, and in the amino acid sequence showing more than 90% homology with the amino acid sequence of sequence number 7, the amino acid at position 300 is proline.

[0052] The "slightly different amino acid sequence" here is produced by deletion, substitution, addition, insertion or a combination thereof of amino acids. Typically, it refers to a mutation (change) in the amino acid sequence by deletion, substitution or addition, insertion or a combination thereof of 1 to several (the upper limit is, for example, 3, 5, 7, 10) amino acids constituting the amino acid sequence. "Slightly different amino acid sequences" are preferably produced by conservative amino acid substitutions. "Conservative amino acid substitutions" here refer to replacing a certain amino acid residue with an amino acid residue having a side chain of the same nature. Amino acid residues are classified into several families according to their side chains, such as basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), non-charged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Conservative amino acid substitutions are preferably substitutions between amino acid residues within the same family. It should be noted that the amino acid residues constituting the active center of the lipase (LIP1) from Candida columnaris (SEQ ID NO: 1) are known to be glutamic acid at position 341, histidine at position 449, and serine at position 209, so when performing mutations, it is sufficient not to affect these amino acid residues. As an example of a slight difference in the amino acid sequence that does not substantially affect the function of the protein and maintains the function of the protein before and after the mutation, there is an amino acid sequence in which the amino acid at position 206 (phenylalanine) of the amino acid sequence of SEQ ID NO: 1 is replaced by tyrosine. The results of comparing the specific activity and the reactivity at high temperature of the lipase having this amino acid sequence are equivalent to those of SEQ ID NO: 1.

[0053] However, the homology (%) of two amino acid sequences or two base sequences (hereinafter "two sequences" is used as a term including them) can be determined, for example, in the following order. First, the two sequences are arranged so that the best comparison can be made (for example, a gap can be introduced into the first sequence to optimize its alignment with the second sequence). When the molecule (amino acid residue or nucleotide) at a specific position of the first sequence is the same as the molecule at the corresponding position of the second sequence, it can be said that the molecules at that position are the same. The homology of two sequences is a function of the number of identical positions common to the two sequences (i.e., homology (%) = number of identical positions / total number of positions × 100), preferably also considering the number and size of the gaps required for optimization of the alignment.

[0054] Comparison of two sequences and determination of homology can be accomplished using mathematical algorithms. Specific examples of mathematical algorithms that can be used for sequence comparison are described in Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87: 2264-68. Although a modified algorithm is described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-77, the algorithm is not limited thereto. Such algorithms are provided in the NBLAST program and the XBLAST program (version 2.0) described in Altschul et al. (1990) J. Mol. Biol. 215: 403-10. To obtain equivalent nucleotide sequences, for example, a BLAST nucleotide search can be performed in the NBLAST program with score = 100 and wordlength = 12. To obtain equivalent amino acid sequences, for example, a BLAST polypeptide search can be performed in the XBLAST program with score = 50 and wordlength = 3. To obtain gapped alignments for comparison, Gapped BLAST as described in Altschul et al. (1997) Amino Acids Research 25(17):3389-3402 can be used. When using BLAST and Gapped BLAST, the default parameters of the corresponding programs (e.g., XBLAST and NBLAST) can be used. For details, please see http: / / www.ncbi.nlm.nih.gov. As an example of other mathematical algorithms that can be used for sequence comparison, there is the algorithm described in Myers and Miller (1988) Comput Appl Biosci. 4:11-17. Such an algorithm is, for example, provided in the ALIGN program that can be used in the GENESTREAM web server (IGH Montpellier, France) or the ISREC server. When using the ALIGN program when comparing amino acid sequences, for example, the PAM120 residue mass table, gap length penalty = 12, gap penalty = 4 can be used.

[0055] The homology between two amino acid sequences can be determined using the GAP program of the GCG software package and using the Blossom 62 matrix or the PAM250 matrix, with gap weights = 12, 10, 8, 6 or 4 and gap length weights = 2, 3 or 4. In addition, the homology between two base sequences can be determined using the GAP program of the GCG software package (available at http: / / www.gcg.com) with gap weights = 50 and gap length weights = 3.

[0056] Typically, the modified enzyme of the present invention is obtained by mutating the lipase consisting of the amino acid sequence of SEQ ID NO. 1, i.e., the lipase from Candida columnaris (one or a combination of two or more of the above-mentioned T130C-S153C, A249P, F259Y, S282P, S283Y and S300P). The substantially homologous lipase described above can be obtained by further applying a mutation to the lipase consisting of the amino acid sequence of SEQ ID NO. 1, applying the same mutation to a lipase consisting of an amino acid sequence having a high homology to the amino acid sequence of SEQ ID NO. 1, such as a lipase derived from the same species and genus as the Candida columnaris strain producing the lipase consisting of the amino acid sequence of SEQ ID NO. 1, or further applying a mutation after the mutation. The "equivalent mutation" here means that in an amino acid sequence having high homology to the amino acid sequence of SEQ ID NO: 1, an amino acid residue equivalent to the amino acid residue at the mutation point of the present invention (position 130, 153, 249, 259, 282, 283 or 300 of the amino acid sequence of SEQ ID NO: 1) is substituted. It should be noted that examples of lipases composed of an amino acid sequence with high homology to the amino acid sequence of sequence number 1 include LIP2 (sequence number 24, sequence homology 79%), LIP3 (sequence number 25, sequence homology 88%), LIP4 (sequence number 26, sequence homology 81%), LIP5 (sequence number 27, sequence homology 82%), which are isozymes of LIP1, a lipase from Diutina rugosa (sequence number 28, sequence homology 87%), a lipase from Candida columnaris (sequence number 29, sequence homology 85%), and a lipase from Candida albicans AC-IITM (sequence number 30, sequence homology 84%).

[0057] The term "equivalent" when used for amino acid residues in this specification refers to the equal contribution to the performance of its function between the compared proteins (enzymes). For example, in a manner that allows for the best comparison while considering the partial identity of the primary structure (amino acid sequence), when the amino acid sequence of the comparison object is arranged relative to the amino acid sequence of the benchmark lipase (amino acid sequence of sequence number 1) (at this time, a gap can be introduced as needed to optimize the comparison), the amino acid at the position corresponding to the specific amino acid in the amino acid sequence of the benchmark can be determined as "equivalent amino acid". It is also possible to replace the comparison between the primary structures or to determine "equivalent amino acid" by comparing the three-dimensional structures (three-dimensional structures) on this basis. By using the three-dimensional structure information, a comparison result with high reliability can be obtained. At this time, a method for comparing the atomic coordinates of the three-dimensional structures of multiple enzymes can be adopted. The three-dimensional structure information of the mutant target enzyme can be obtained, for example, from Protein Data Bank (http: / / www.pdbj.org / index_j.html).

[0058] An example of a method for determining the three-dimensional structure of a protein using X-ray crystal structure analysis is shown below.

[0059] (1) Crystallizing the protein. Crystallization is essential for determining the three-dimensional structure. In addition, it is also industrially useful as a method for purifying proteins to high purity and storing them at high density and stability. In this case, the protein bound to a substrate or a similar compound thereof as a ligand can be crystallized.

[0060] (2) Irradiate the prepared crystals with X-rays and collect diffraction data. It should be noted that protein crystals are often damaged by X-ray irradiation, resulting in a decrease in diffraction ability. In this case, a low-temperature measurement technique has recently become popular, which involves rapidly cooling the crystals to around -173°C and collecting diffraction data in this state. It should be noted that, ultimately, in order to collect high-resolution data for structure determination, a high-brightness synchrotron radiation source can be used.

[0061] (3) In the analysis of crystal structure, in addition to diffraction data, phase information is also required. For the target protein, if the crystal structure of the closely related protein is unknown, it is impossible to determine the structure using the molecular replacement method, and the phase problem must be solved by the heavy atom isomorphous replacement method. The heavy atom isomorphous replacement method is a method of introducing metal atoms with large atomic numbers such as mercury and platinum into crystals, and using the contribution of the large X-ray scattering ability of the metal atoms to the X-ray diffraction data to obtain phase information. The determined phase can be improved by smoothing the electron density in the solvent region of the crystal. Since the water molecules in the solvent region fluctuate greatly, the electron density is almost unobservable. Therefore, by approximating the electron density in this region to 0, it is possible to approach the true electron density and even improve the phase. In addition, when the asymmetric unit contains multiple molecules, the phase can be improved more significantly by averaging the electron density of these molecules. The protein model is fitted in the electron density map calculated using the improved phase. This process is performed on a computer map using programs such as QUANTA of MSI (USA). Afterwards, the structure is refined using programs such as X-PLOR of MSI to complete the structural analysis. If the crystal structure of a related protein is known, the target protein can be determined by molecular replacement using the atomic coordinates of the known protein. Molecular replacement and structural refinement can be performed using a program such as CNS_SOLVE ver.11.

[0062] 2. Nucleic acid encoding modified lipase, etc.

[0063] The second aspect of the present invention provides a nucleic acid related to the modified enzyme of the present invention. That is, the present invention provides a gene encoding a modified enzyme, a nucleic acid that can be used as a probe to identify a nucleic acid encoding a modified enzyme, and a nucleic acid that can be used as a primer to amplify or mutate a nucleic acid encoding a modified enzyme.

[0064] Genes encoding modified enzymes are typically used for the preparation of modified enzymes. According to the genetic engineering preparation method using genes encoding modified enzymes, a more homogeneous modified enzyme can be obtained. In addition, this method can also be referred to as a preferred method for preparing a large number of modified enzymes. It should be noted that the use of genes encoding modified enzymes is not limited to the preparation of modified enzymes. For example, as an experimental tool for the purpose of clarifying the mechanism of action of modified enzymes, or as a tool for designing or making further modified forms of enzymes, the nucleic acid can also be used.

[0065] In this specification, "gene encoding modified enzyme" refers to a nucleic acid that obtains the modified enzyme when expressed, and of course includes a nucleic acid having a base sequence corresponding to the amino acid sequence of the modified enzyme, and of course also includes a nucleic acid formed by adding a sequence that does not encode an amino acid sequence to such a nucleic acid. In addition, the degeneracy of codons is also considered.

[0066] Examples of sequences (base sequences) of genes encoding modified enzymes are shown in SEQ ID NOs: 8 to 13. These sequences encode mutants described in the Examples described below as follows.

[0067] SEQ ID NO: 8: Mutant 1 (T130C-S153C)

[0068] SEQ ID NO. 9: Mutant 2 (A249P)

[0069] SEQ ID NO: 10: Mutant 3 (F259Y)

[0070] SEQ ID NO: 11: Mutant 4 (S282P)

[0071] SEQ ID NO: 12: Mutant 5 (S283Y)

[0072] SEQ ID NO. 13: Mutant 6 (S300P)

[0073] However, in Candida columnaris, the CTG codon encodes serine. When other yeasts are used as hosts for expression, the CTG codon needs to be changed to other codons (TCT, TCC, TCA, AGT or AGC) encoding serine according to the host used. As a gene sequence for heterologous expression, a sequence in which any one of sequence numbers 8 to 13 has been subjected to such codon substitution is also provided. Examples of sequences in which codon substitution has been applied are shown below.

[0074] SEQ ID NO: 14 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 8)

[0075] SEQ ID NO: 15 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 9)

[0076] SEQ ID NO: 16 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 10)

[0077] SEQ ID NO: 17 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 11)

[0078] SEQ ID NO: 18 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 12)

[0079] SEQ ID NO: 19 (sequence in which codon substitution was performed in the sequence of SEQ ID NO: 13)

[0080] When the gene of the present invention is expressed in a host, a gene construct in which a sequence encoding a signal peptide (signal sequence) is attached to the 5' end of the above sequence (any one of sequence numbers 8 to 19) is usually introduced into the host. An example of a signal sequence (the signal sequence of a wild-type lipase from Candida columnaris is shown in sequence number 20. The amino acid sequence encoded by the sequence (i.e., the signal peptide) is shown as sequence number 21. The signal sequence can be selected according to the host. As long as it is a signal sequence that can express the mutant as the target, it can be used in the present invention. As an example of a usable signal sequence, a sequence encoding a signal peptide of α-factor (Protein Engineering, 1996, vol9, p.1055-1061), a sequence encoding a signal peptide of an α-factor receptor, a sequence encoding a signal peptide of a SUC2 protein, a sequence encoding a signal peptide of a PHO5 protein, a sequence encoding a signal peptide of a BGL2 protein, a sequence encoding a signal peptide of an AGA2 protein, a sequence encoding a signal peptide of a TorA (trimethylamine N-oxidoreductase), a sequence encoding a signal peptide of a PhoD (phosphatase) from Bacillus subtilis, a sequence encoding a signal peptide of a LipA (lipase) from Bacillus subtilis, a sequence encoding a signal peptide of a diastase from Aspergillus oryzae (Japanese Patent Application Laid-Open No. 2009-60804), a sequence encoding a signal peptide of an α-amylase from Bacillus amyloliquefaciens (Eur. J. Biochem. 155, 577-581 (1986)), a sequence encoding a signal peptide of a neutral protease from Bacillus subtilis (APPLIED AND ENVIRONMENTAL MICROBIOLOGY, April 1995, p. 1610-1613 Vol. 61, No. 4), a sequence encoding a signal peptide of a cellulase derived from a bacterium of the genus Bacillus (Japanese Patent Application Laid-Open No. 2007-130012).

[0081] The nucleic acid of the present invention can be prepared in an isolated state by using standard genetic engineering methods, molecular biology methods, biochemical methods, chemical synthesis, etc., with reference to the sequence information disclosed in the present specification or the attached sequence listing.

[0082] In another embodiment of the present invention, a nucleic acid is provided that has the same function as the protein encoded by the gene encoding the modified enzyme of the present invention but has a different base sequence in a part (hereinafter also referred to as "identical nucleic acid". In addition, the base sequence of the specified identical nucleic acid is also referred to as "identical base sequence"). As an example of an identical nucleic acid, a DNA encoding a protein having an enzyme activity (i.e., lipase activity) characteristic of a modified enzyme, which is composed of a base sequence containing substitutions, deletions, insertions, additions or inversions of one or more bases, based on the base sequence of the nucleic acid encoding the modified enzyme of the present invention. Substitutions, deletions, etc. of bases can occur at multiple sites. The "multiple" here may vary depending on the position and type of amino acid residues in the three-dimensional structure of the protein encoded by the nucleic acid, but for example, it is 2 to 40 bases, preferably 2 to 20 bases, and more preferably 2 to 10 bases.

[0083] The identical nucleic acid has, for example, 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 85% or more, further preferably about 90% or more, further more preferably 95% or more, and most preferably 99% or more homology with respect to the base sequence serving as a reference.

[0084] The above identical nucleic acids can be obtained, for example, by restriction endonuclease treatment, treatment with exonucleases, DNA ligases, etc., by site-specific mutagenesis (Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York), random mutagenesis (Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York), etc. In addition, identical nucleic acids can also be obtained by other methods such as ultraviolet irradiation.

[0085] Another embodiment of the present invention relates to a nucleic acid having a base sequence complementary to the base sequence of the gene encoding the modified enzyme of the present invention. Still another embodiment of the present invention provides a nucleic acid having a base sequence that is at least about 60%, 70%, 80%, 90%, 95%, 99%, or 99.9% identical to the base sequence of the gene encoding the modified enzyme of the present invention, or a base sequence complementary thereto.

[0086] Another embodiment of the present invention relates to a nucleic acid having a base sequence that hybridizes under stringent conditions to a base sequence complementary to a base sequence of a gene encoding a modified enzyme of the present invention or its identical base sequence. "Stringent conditions" herein refer to conditions that form a so-called specific hybridization and do not form non-specific hybridization. Such stringent conditions are well known to those skilled in the art, and can be set, for example, with reference to Molecular Cloning (Third Edition, Cold Spring Harbor Laboratory Press, New York), Current protocols in molecular biology (edited by Frederick M. Ausubel et al., 1987). Examples of stringent conditions include a hybridization solution (50% formamide, 10×SSC (0.15 M NaCl, 15 mM sodium citrate, pH 7.0), 5×Denhardt's solution, 1% SDS, 10% dextran sulfate, 10 μg / ml denatured salmon sperm DNA, 50 mM phosphate buffer (pH 7.5)), incubation at about 42° C. to about 50° C., followed by washing at about 65° C. to about 70° C. using 0.1×SSC, 0.1% SDS. More preferred stringent conditions include a hybridization solution containing 50% formamide, 5×SSC (0.15 M NaCl, 15 mM sodium citrate, pH 7.0), 1×Denhardt's solution, 1% SDS, 10% dextran sulfate, 10 μg / ml denatured salmon sperm DNA, 50 mM phosphate buffer (pH 7.5)).

[0087] Another embodiment of the present invention provides a nucleic acid (nucleic acid fragment) having a base sequence of a gene encoding a modified enzyme of the present invention, or a portion of a base sequence complementary thereto. Such a nucleic acid fragment can be used to detect, identify and / or amplify a nucleic acid having a base sequence of a gene encoding a modified enzyme of the present invention, etc. The nucleic acid fragment is, for example, designed to contain at least a portion that hybridizes with a continuous nucleotide portion (e.g., about 10 to about 100 bases in length, preferably about 20 to about 100 bases in length, and more preferably about 30 to about 100 bases in length) in the base sequence of the gene encoding the modified enzyme of the present invention. The nucleic acid fragment can be labeled when used as a probe. Labeling can use, for example, fluorescent substances, enzymes, and radioactive isotopes.

[0088] Another aspect of the present invention relates to a recombinant DNA containing the gene of the present invention (gene encoding a modified enzyme). The recombinant DNA of the present invention is provided, for example, in the form of a vector. The term "vector" in this specification refers to a nucleic acid molecule capable of transporting a nucleic acid inserted therein to a target such as a cell.

[0089] An appropriate vector is selected according to the purpose of use (cloning, protein expression) and the type of host cell. Examples of vectors using Escherichia coli as a host include M13 phage or its modified form, lambda phage or its modified form, pBR322 or its modified form (pB325, pAT153, pUC8, etc.), examples of vectors using yeast as a host include pYepSec1, pMFa, pYES2, pPIC3.5K, etc., examples of vectors using insect cells as a host include pAc, pVL, etc., and examples of vectors using mammalian cells as a host include pCDM8, pMT2PC, etc.

[0090] The vector of the present invention is preferably an expression vector. "Expression vector" refers to a vector that can introduce a nucleic acid inserted thereinto into a target cell (host cell) and can be expressed in the cell. An expression vector generally contains a promoter sequence required for the expression of the inserted nucleic acid, an enhancer sequence that promotes expression, and the like. An expression vector containing a selection marker can also be used. When using the expression vector, a selection marker can be used to confirm whether the expression vector has been introduced (and to what extent).

[0091] Insertion of the nucleic acid of the present invention into a vector, insertion of a selection marker gene (if necessary), insertion of a promoter (if necessary), etc. can be carried out using standard recombinant DNA technology (for example, refer to Molecular Cloning, Third Edition, 1.84, Cold Spring Harbor Laboratory Press, New York, a well-known method using a restriction endonuclease and a DNA ligase).

[0092] As a host cell, from the viewpoint of easy handling, microorganisms such as Aspergillus (e.g., Aspergillus oryzae), Bacillus bacteria (e.g., Bacillus subtilis), Escherichia coli (Escherichia coli), and budding yeast (Saccharomyces cerevisiae) can be used, but as long as the host cell in which the recombinant DNA can be replicated and the gene of the modified enzyme can be expressed can be used. Preferably, Escherichia coli (Escherichia Koli) and budding yeast (Saccharomyces cerevisiae) can be used. Candida yeast (e.g., Candida columnaris) can also be used as a host. In addition, Pichia yeast (e.g., Pichia pastoris) can also be used as a host. As an example of Escherichia coli, Escherichia coli BL21 (DE3) pLysS can be enumerated when utilizing T7 system promoters, and Escherichia coli JM109 can be enumerated if this is not the case. In addition, as an example of budding yeast, budding yeast SHY2, budding yeast AH22, or budding yeast INVSc1 (Invitrogen company) can be enumerated.

[0093] Another aspect of the present invention relates to a microorganism (ie, a transformant) having the recombinant DNA of the present invention. The microorganism of the present invention can be obtained by transfection or transformation using the above-mentioned vector of the present invention. For example, it can be carried out by the calcium chloride method (Journal of Molecular Biology (J.Mol.Biol.), Vol. 53, p. 159 (1970)), the Hanahan method (Journal of Molecular Biology, Vol. 166, p. 557 (1983)), the SEM method (Gene, Vol. 96, p. 23 (1990)), the method of Chung et al. (Proceedings of the National Academy of Sciences of the USA, Vol. 86, p. 2172 (1989)), the calcium phosphate coprecipitation method, electroporation (Potter, H. et al., Proc. Natl. Acad. Sci. USA 81, 7161-7165 (1984)), lipofection (Felgner, P et al., Proc. Natl. Acad. Sci. USA 84, 7413-7417 (1984)), etc. It should be noted that the microorganism of the present invention can be used to produce the modified enzyme of the present invention.

[0094] 3. Enzyme preparations containing modified lipase

[0095] The modified enzyme of the present invention is provided, for example, in the form of an enzyme preparation. In addition to containing an active ingredient (modified enzyme of the present invention), the enzyme preparation may also contain an excipient, a buffer, a suspending agent, a stabilizer, a preservative, a preservative, a physiological saline solution, etc. As an excipient, starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, white sugar, glycerol, etc. may be used. As a buffer, phosphates, citrates, acetates, etc. may be used. As a stabilizer, propylene glycol, ascorbic acid, etc. may be used. As a preservative, phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methyl parahydroxybenzoate, etc. may be used. As a preservative, ethanol, benzalkonium chloride, parahydroxybenzoic acid, chlorobutanol, etc. may be used.

[0096] 4. Uses of modified lipase

[0097] Another aspect of the present invention relates to the use of modified enzymes and enzyme preparations, and various reactions (hydrolysis, synthesis, transfer) using the modified enzymes or enzyme preparations of the present invention are provided. Specifically, the modified enzymes or enzyme preparations of the present invention can be used in the decomposition of oils and fats in oil-containing wastewater, grease separators, food processing (e.g., the manufacture of milk flavor, the decomposition of oils and fats, the manufacture of FPA·DHA, bread making, egg white processing), organic synthesis reactions (e.g., optical resolution of racemates, asymmetricization of symmetrical compounds, position-selective acylation of hydroxyl groups), etc. The modified enzymes of the present invention have excellent reactivity and stability at high temperatures. This characteristic particularly improves the reactivity relative to oils and fats (oils and fats containing saturated fatty acids, animal oils and fats, etc.) solidified at room temperature, and acts advantageously in the above-mentioned uses. Below, as a specific example of use, a method for decomposing oils and fats in wastewater in which a lipase reaction at high temperature is desired is described. In many cases, the oils and fats present in wastewater and grease separators include oils and fats (e.g., animal oils and fats such as lard and tallow) that have high melting points and solidification points and are difficult to hydrolyze at room temperature (20°C ± 10°C). The oil decomposition method of the present invention is useful for efficiently decomposing such oils and fats. Therefore, the oil decomposition method of the present invention preferably uses substances (oil-containing substances) containing oils and fats with high melting points and solidification points as decomposition objects. Examples of such oil-containing substances are drainage from restaurants, hospitals, hotels, etc., household drainage, industrial wastewater discharged from food processing factories, oil processing factories, etc., drainage and accumulation in grease separators installed in kitchens, etc. It should be noted that a "grease separator" is a device for separating and collecting oil in drainage, and is typically composed of three tanks. The first tank is equipped with a basket for collecting food, leftovers, etc. The second tank separates oil from water. The drainage separated from the oil is sent to the third tank to remove sedimentary garbage, etc. A grease separator needs to be installed in business kitchens of restaurants, hospitals, hotels, etc.

[0098] In the oil decomposition method of the present invention, the modified enzyme of the present invention is allowed to act on the oil-containing material as described above. For example, the modified enzyme of the present invention or the enzyme preparation is added to a solution containing the oil-containing material, and the modified enzyme of the present invention is in contact with the oil-containing material to carry out an enzyme reaction. In order to utilize the characteristics of the present invention and achieve efficient hydrolysis, it is preferred to carry out the reaction at a high temperature. The high temperature here is 30°C to 70°C, preferably 40 to 65°C, and more preferably 45 to 60°C. The reaction time can be set to obtain the desired decomposition rate by taking into account the type, amount, and amount of enzyme used of the oil-containing material to be treated. If an example of the reaction time is shown, it is 1 hour to 2 days.

[0099] 5. Preparation of modified lipase

[0100] Another aspect of the present invention relates to a method for preparing a modified enzyme. In one embodiment of the preparation method of the present invention, a modified enzyme successfully prepared by the inventors is prepared by a genetic engineering method. In the case of this embodiment, a nucleic acid encoding any one of the amino acid sequences in sequence numbers 2 to 7 is prepared (step (I)). Here, "nucleic acid encoding a specific amino acid sequence" refers to a nucleic acid that obtains a polypeptide having the amino acid sequence when expressed. A nucleic acid consisting of a base sequence corresponding to the amino acid sequence is of course possible, and an extra sequence (either a sequence encoding an amino acid sequence or a sequence that does not encode an amino acid sequence) may be added to such a nucleic acid. In addition, the degeneracy of codons is also considered. "Nucleic acid encoding any one of the amino acid sequences in sequence numbers 2 to 7" can be prepared in an isolated state by using standard genetic engineering methods, molecular biology methods, biochemical methods, etc., with reference to the sequence information disclosed in this specification or the attached sequence table. Here, the amino acid sequences of sequence numbers 2 to 7 are all sequences in which the amino acid sequence of the lipase from Candida columnaris is mutated. Therefore, even by applying the necessary mutations to the gene encoding the lipase from Candida columnaris, a nucleic acid (gene) encoding any of the amino acid sequences of SEQ ID NOs. 2 to 7 can be obtained. Many methods for position-specific base sequence substitution are known in the art (for example, see Molecular Cloning, Third Edition, Cold Spring Harbor Laboratory Press, New York), and an appropriate method can be selected and used. As a method for introducing position-specific mutations, a position-specific amino acid saturation mutation method can be used. The position-specific amino acid saturation mutation method is a "Semi-rational, semi-random: semi-rational and semi-random" method (J. Mol. Biol. 331, 585-592 (2003)) that introduces amino acid saturation mutations based on the three-dimensional structure of the protein and infers the position related to the desired function. For example, a kit such as Quick change (Stratagene) and overlap extension PCR (Nucleic Acid Res. 16, 7351-7367 (1988)) can be used to introduce position-specific amino acid saturation mutations. Taq polymerase or the like can be used as the DNA polymerase used for PCR. Among them, it is preferable to use a DNA polymerase having high precision, such as KOD-PLUS- (Toyobo Co., Ltd.) and Pfu turbo (Stratagene Co., Ltd.).

[0101] Following step (I), the prepared nucleic acid is expressed (step (II)). For example, an expression vector into which the above nucleic acid is inserted is first prepared, and a host cell is transformed using the expression vector.

[0102] Next, the transformant is cultured under conditions in which the modified enzyme as the expression product is produced. The culture of the transformant can be carried out according to a common method. As a carbon source for the culture medium, it can be a carbon compound that can be assimilated, for example, glucose, sucrose, lactose, maltose, molasses, pyruvic acid, etc. can be used. In addition, as a nitrogen source, it can be a nitrogen compound that can be utilized, for example, peptone, meat extract, yeast extract, casein hydrolyzate, soybean meal alkali extract, etc. can be used. In addition, salts such as phosphates, carbonates, sulfates, magnesium, calcium, potassium, iron, manganese, zinc, specific amino acids, specific vitamins, etc. can be used as needed.

[0103] On the other hand, the culture temperature can be set within the range of 30°C to 40°C (near 37°C). The culture time can be set in consideration of the growth characteristics of the transformant of the culture object, the production characteristics of the modified enzyme, etc. The pH of the culture medium is prepared to be within the range in which the transformant grows and produces the enzyme. It is preferred that the pH of the culture medium be 6.0 to 9.0 (preferably around pH 7.0).

[0104] Next, the expression product (modified enzyme) is recovered (step (III)). The culture solution containing the cultured bacterial cells can be used as an enzyme solution directly or after concentration, impurity removal, etc., but generally, the expression product is temporarily recovered from the culture solution or bacterial cells. If the expression product is a secretory protein, it can be recovered from the culture solution, otherwise it can be recovered from the bacterial body. When recovering from the culture solution, for example, after filtering the culture supernatant and centrifuging to remove insoluble matter, separation and purification are carried out by combining reduced pressure concentration, membrane concentration, salting out using ammonium sulfate or sodium sulfate, fractional precipitation using methanol, ethanol or acetone, dialysis, heat treatment, isoelectric point treatment, gel filtration, various chromatography using adsorption chromatography, ion exchange chromatography, affinity chromatography, etc. (for example, gel filtration using Sephadex gel (GE Healthcare Bioscience), DEAE Sepharose CL-6B (GE Healthcare Bioscience), Octyl Sepharose CL-6B (GE Healthcare Bioscience), CM Sepharose CL-6B (GE Healthcare Bioscience)), etc., to obtain a purified modified enzyme. On the other hand, when recovering from within the bacteria, the bacteria are collected by filtering the culture solution, centrifuging it, etc., and then the bacteria are destroyed by mechanical methods such as pressurization, ultrasonic treatment, physical pulverization, or by enzymatic methods based on lysozyme, etc., and then separated and purified in the same way as above to obtain a refined product of the modified enzyme.

[0105] The purified enzyme obtained as described above can also be powdered and provided, for example, by freeze drying, vacuum drying or spray drying. At this time, the purified enzyme can be pre-dissolved in a phosphate buffer, a triethanolamine buffer, a tris buffer, or a GOOD buffer. Preferably, a phosphate buffer or a triethanolamine buffer can be used. It should be noted that, as a GOOD buffer, PIPES, MES or MOPS can be cited.

[0106] Generally, as described above, an appropriate host-carrier system is used to express the gene and to recover the expression product (modified enzyme), but a cell-free synthesis system can also be used. Here, "cell-free synthesis system (cell-free transcription system, cell-free transcription / translation system)" refers to the use of ribosomes, transcription / translation factors, etc. from living cells (or obtained by genetic engineering methods) without using living cells, and synthesizing the mRNA and protein encoded by nucleic acids (DNA, mRNA) as templates in vitro. In the cell-free synthesis system, a cell extract obtained by refining the cell pulverization liquid as needed is generally used. The cell extract generally contains various factors such as ribosomes, initiation factors, and various enzymes such as tRNA required for protein synthesis. When synthesizing protein, various amino acids, energy sources such as ATP, GTP, and other substances required for protein synthesis such as creatine phosphate are added to the cell extract. Of course, it is also possible to supplement ribosomes, various factors, and / or various enzymes prepared separately as needed when synthesizing protein.

[0107] The development of a transcription / translation system for reconstructing each molecule (factor) required for protein synthesis has also been reported (Shimizu, Y. et al.: Nature Biotech., 19, 751-755, 2001). In this synthesis system, genes for 31 factors, including 3 initiation factors, 3 elongation factors, 4 factors related to termination, 20 aminoacyl-tRNA synthetases that bind each amino acid to tRNA, and methionyl-tRNA formyltransferase, that constitute the protein synthesis system of bacteria are amplified from Escherichia coli, and the protein synthesis system is reconstructed in vitro using these. Such a reconstructed synthesis system can be used in the present invention.

[0108] The term "cell-free transcription / translation system" can be used interchangeably with a cell-free protein synthesis system, an in vitro translation system or an in vitro transcription / translation system. In the in vitro translation system, RNA is used as a template to synthesize protein. As template RNA, total RNA, mRNA, in vitro transcription products, etc. can be used. In another in vitro transcription / translation system, DNA is used as a template. The template DNA preferably should include a ribosome binding region and include an appropriate termination sequence. It should be noted that in the in vitro transcription / translation system, the conditions for adding the factors required for each reaction are set in a manner that the transcription reaction and the translation reaction are carried out continuously.

[0109] Example

[0110] <Search for a mutation point that is effective for improving reactivity or stability at high temperatures>

[0111] The goal is to improve the high temperature reactivity or high temperature stability of the lipase from Candida columnaris (SEQ ID NO. 1). From the perspectives of disulfide bond formation, ring immobilization (pre-introduction), hydrogen bond strengthening and hydrophobicity strengthening, mutation points (substituted amino acid residues) were selected to design 22 mutants (modified lipases). Each designed mutant was prepared according to the following method and its characteristics were evaluated. It should be noted that the amino acid sequence of SEQ ID NO. 1 is the mature form of the lipase from Candida columnaris (without a signal peptide), and the amino acid sequence that also contains a signal peptide and the gene sequence encoding it are shown in SEQ ID NO. 22 and SEQ ID NO. 23, respectively.

[0112] (1) Obtaining a DNA sequence encoding a mutant amino acid sequence

[0113] The Pichia pastoris host expression system (Invitrogen, Pichia Expression Kit) was used. The plasmid used was pPIC3.5K, and the LIP1 gene from Candida columnaris used as a template used the codon sequence most suitable for budding yeast (Saccharomyces cerevisiae). The inverse PCR method was used to introduce mutations (Takara Bio Primestar mutagenesis kit) to prepare genes encoding various mutants that produced amino acid substitutions at the selected mutation points (sequence numbers 14 to 19). The plasmid containing the mutant LIP1 gene was transformed into E. coli DH5α. Next, the plasmid containing the mutant LIP1 gene was extracted from the transformed E. coli.

[0114] (2) Transformation of Pichia pastoris and preparation of enzyme solution

[0115] The plasmid containing the mutant LIP1 gene is transformed into Pichia pastoris GS115 (Invitrogen, Pichia Expression Kit). The resulting Pichia pastoris transformant is cultured, and the culture supernatant is recovered. The culture can be carried out by the method described in the kit. For example, a Pichia transformant is inoculated into a BMGY medium (2.0% peptone, 1.0% yeast extract, 100 mM potassium phosphate pH 6.0, 1.34% yeast nitrogen base (without amino acids), 0.4 μg / mL biotin, 1.0% glycerol), and cultured with shaking at 30°C for 2 days in a test tube. The culture solution is inoculated into a baffled flask filled with 50 mL of BMMY medium (2.0% peptone, 1.0% yeast extract, 100 mM potassium phosphate pH 6.0, 1.34% yeast nitrogen base (without amino acids), 0.4 μg / mL biotin, 0.5% methanol), and cultured at 30°C and 200 rpm for 1 day. After the bacteria are collected, they are suspended in 50 mL of BMMY medium and cultured under the same conditions in a baffled flask. Methanol is added every about 12 hours to a final concentration of 0.5%, and the enzyme expression is induced for 4 days. The recovered culture supernatant (crude enzyme solution) was used to evaluate the properties (high temperature reactivity and high temperature stability) of each mutant, and 8 mutants that were considered to have improved properties compared with the wild type were selected.

[0116] (3) Purification of mutant (modified lipase)

[0117] The culture supernatant of the selected mutant was desalted and concentrated, and replaced with 20 mM McIlvaine buffer (pH 3.8). The replaced solution was added to an SP-agarose (GE healthcare) column equilibrated with the same buffer. Elution was performed using a linear gradient from 0 to 0.5 mol / L NaCl, and the fraction showing lipase activity was recovered to obtain a purified enzyme.

[0118] (4) Evaluation of high temperature reactivity

[0119] For each purified enzyme, the enzyme activity at 30°C and 60°C was measured using a lipase activity detection kit S (DS BIOPHARMAMEDICAL) to confirm that the high temperature reactivity was improved. The high temperature reactivity was evaluated by the relative activity (ratio of the enzyme activity at 60°C to the enzyme activity at 30°C) calculated using the following calculation formula.

[0120] Relative activity = (enzyme activity at 60°C / enzyme activity at 30°C) × 100 (%)

[0121] The evaluation results are shown in Figure 1It was observed that the six mutants had improved high temperature reactivity. Mutant 1 (T130C-S153C) and mutant 5 (S283Y) were particularly highly reactive at high temperatures.

[0122] (5) Evaluation of high temperature stability

[0123] Each purified enzyme was diluted with a phosphate buffer (pH 6.0) so that the absorbance at 280 nm (A280) was equal, heated at 50°C for 30 minutes, and then cooled with ice. Then, the sample was centrifuged and the enzyme activity of the centrifuged supernatant of each sample was measured using a lipase activity detection kit S (DSBIOPHARMAMEDICAL). Based on the measurement results (enzyme activity after heat treatment) and the enzyme activity before heat treatment, the activity residual rate was calculated as follows to evaluate the high temperature stability.

[0124] Remaining activity rate = (enzyme activity after heat treatment / enzyme activity before heat treatment) × 100 (%)

[0125] The evaluation results are shown in Figure 2 It was found that the six mutants had improved high temperature stability. Mutant 2 (A249P), mutant 5 (S283Y) and mutant 6 (S300P) were particularly stable at high temperatures.

[0126] As described above, six mutants excellent in high temperature reactivity or high temperature stability were successfully obtained. The amino acid sequences of the respective mutants are shown below.

[0127] Mutant 1 (T130C-S153C): SEQ ID NO: 2

[0128] Mutant 2 (A249P): Sequence No. 3

[0129] Mutant 3 (F259Y): Sequence No. 4

[0130] Mutant 4 (S282P): Sequence number 5

[0131] Mutant 5 (S283Y: SEQ ID NO: 6

[0132] Mutant 6 (S300P): Sequence No. 7

[0133] Industrial Applicability

[0134] The modified lipase of the present invention is excellent in reactivity and stability at high temperatures, and therefore has particularly high utility value in various applications requiring reactions at high temperatures.

[0135] The present invention is not limited by the embodiments and examples of the above invention. Various modifications within the scope that can be easily thought of by those skilled in the art are also included in the present invention without departing from the scope of patent protection. The contents of papers, open patent publications, patent publications, etc. clearly stated in this specification are cited in their entirety by reference. Sequence Listing <110> AMANO ENZYME PRODUCTS CO., LTD. <120> Modified lipase and its use <130> AE17002P <150> JP P2017-168995 <151> 2017-09-01 <160> 30 <170> PatentIn version 3.5 <210> 1 <211> 534 <212> PRT <213> Candida columnaris <400> 1 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 2 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> Mutant Enzyme 1 (T130C - S153C) <400> 2 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Cys Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Cys Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 3 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> Mutant Enzyme 2 (A249P) <400> 3 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Pro Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 4 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> Mutant Enzyme 3 (F259Y) <400> 4 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Tyr Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Serum Phe Phe Val 530 <210> 5 <211> 534 <212> PRT <213> artificial sequence <220> <223> Mutants 4(S282P) <400> 5 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Pro Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 6 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> Mutant Enzyme 5 (S283Y) <400> 6 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Tyr Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 7 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> Mutant Enzyme 6 (S300P) <400> 7 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asp Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn 245 250 255 Glu Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Pro Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 8 <211> 1605 <212> DNA <213> The snowstorm <220> <223> Section 1(T130C-S153C) <400> 8 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggctgt agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgtgtg tcaactaccg cgtgtcgtcg 480 tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gacaacattg cggcgtttgg cggcgacccg 600 accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc 660 tggaacgacg gcgacaacac gtacaagggc aagccgctct tccgcgcggg catcatgcag 720 ctgggggcca tggtgccgct ggacgccgtg gacggcatct acggcaacga gatctttgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgctgagcg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtactcc 900 tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1020 gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag 1080 tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttcctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 9 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 2 (A249P) <400> 9 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac 60 gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggcacc agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgagcg tcaactaccg cgtgtcgtcg tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gacaacattg cggcgtttgg cggcgacccg accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc tggacgacg gcgacaacc gtacaagggc aagccgctct tccgcgcggg catcatgcag ctgggggcca tggtgccgct ggacccggtg gacggcatct acggcaacga gatctttgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgctgagcg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtactcc 900 tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1020 gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag 1080 tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 10 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 3 (F259Y) <400> 10 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac 60 gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg 240 gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggcacc agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgagcg tcaactaccg cgtgtcgtcg 480 tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gaacattg cggcgtttgg cggcgacccg 600 accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc 660 tggaacgacg gcgacaacac gtacaagggc aagccgctct tccgcgcggg catcatgcag 720 ctggggcca tggtgccgct ggacgccgtg gacggcatct acggcaacga gatctacgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgctgagcg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtactcc 900 tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1020 gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag 1080 tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttcctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 11 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 4 (S282P) <400> 11 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac 60 gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg 240 gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggcacc agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgagcg tcaactaccg cgtgtcgtcg tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gacaacattg cggcgtttgg cggcgacccg accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc tggacgacg gcgacaacc gtacaagggc aagccgctct tccgcgcggg catcatgcag ctgggggcca tggtgccgct ggacgccgtg gacggcatct acggcaacga gatctttgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgccgagcg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtactcc 900 tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1020 gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag 1080 tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttcctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 12 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant enzyme 5 (S283Y) <400> 12 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac 60 gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg 240 gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggcacc agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgagcg tcaactaccg cgtgtcgtcg 480 tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gacaacattg cggcgtttgg cggcgacccg 600 accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc 660 tggaacgacg gcgacaacac gtacaagggc aagccgctct tccgcgcggg catcatgcag 720 ctggggcca tggtgccgct ggacgccgtg gacggcatct acggcaacga gatctttgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgctgtacg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtactcc 900 tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1020 gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag 1080 tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 13 <211> 1605 <212> DNA <213> Artificial sequence <220> <223> Mutant enzyme 6 (S300P) <400> 13 gcccccaccg ccacgctcgc caacggcgac accatcaccg gtctcaacgc catcatcaac 60 gaggcgttcc tcggcattcc ctttgccgag ccgccggtgg gcaacctccg cttcaaggac 120 cccgtgccgt actccggctc gctcgatggc cagaagttca cgctgtacgg cccgctgtgc 180 atgcagcaga accccgaggg cacctacgag gagaacctcc ccaaggcagc gctcgacttg 240 gtgatgcagt ccaaggtgtt tgaggcggtg ctgccgctga gcgaggactg tctcaccatc 300 aacgtggtgc ggccgccggg caccaaggcg ggtgccaacc tcccggtgat gctctggatc 360 tttggcggcg ggtttgaggt gggtggcacc agcaccttcc ctcccgccca gatgatcacc 420 aagagcattg ccatgggcaa gcccatcatc cacgtgagcg tcaactaccg cgtgtcgtcg tgggggttct tggctggcga cgagatcaag gccgagggca gtgccaacgc cggtttgaag 540 gaccagcgct tgggcatgca gtgggtggcg gacaacattg cggcgtttgg cggcgacccg accaaggtga ccatctttgg cgagctggcg ggcagcatgt cggtcatgtg ccacattctc tggacgacg gcgacaacc gtacaagggc aagccgctct tccgcgcggg catcatgcag ctgggggcca tggtgccgct ggacgccgtg gacggcatct acggcaacga gatctttgac 780 ctcttggcgt cgaacgcggg ctgcggcagc gccagcgaca agcttgcgtg cttgcgcggt 840 gtgctgagcg acacgttgga ggacgccacc aacaacaccc ctgggttctt ggcgtacccg tcgttgcggt tgctgtacct cccccggccc gacggcgtga acatcaccga cgacatgtac 960 gccttggtgc gcgagggcaa gtatgccaac atccctgtga tcatcggcga ccagaacgac 1080. gagggcacct tctttggcac cctgctgttg aacgtgacca cggatgccca ggcccgcgag tacttcaagc agctgtttgt ccacgccagc gacgcggaga tcgacacgtt gatgacggcg 1140 taccccggcg acatcaccca gggcctgccg ttcgacacgg gtattctcaa cgccctcacc 1200 ccgcagttca agagaatcct ggcggtgctc ggcgaccttg gctttacgct tgctcgtcgc 1260 tacttcctca accactacac cggcggcacc aagtactcat tcctcctgaa gcagctcctg 1320 ggcttgccgg tgctcggaac gttccactcc aacgacattg tcttccagga ctacttgttg 1380 ggcagcggct cgctcatcta caacaacgcg ttcattgcgt ttgccacgga cttggacccc 1440 aacaccgcgg ggttgttggt gaagtggccc gagtacacca gcagcctgca gctgggcaac 1500 aacttgatga tgatcaacgc cttgggcttg tacaccggca aggacaactt ccgcaccgcc 1560 ggctacgacg cgttgttctc caacccgccg ctgttctttg tgtga 1605 <210> 14 <211> 1605 <212> DNA <213> Artificial sequence <220> <223> Mutant enzyme 1 (T130C - S153C) <400> 14 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac 60 gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 180. ccgtacctt actcaggttc attggacggt cagaattca cctcttacgg tccatcttgt 240. atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt aacgtcgtta ggcctcctgg aaccaaagcc ggtgctaatt tgcctgtcat gttatggatc 360 ttcggaggag gttttgaagt tggaggttgt tctacatttc cacctgccca gatgatcaca 420 480. aaatctatcg ccatgggaaa gcctattatc cacgtatgtg tcaactatag ggtttcatct tggggttttt tagctggaga cgaaatcaag gctgaaggat cagcaaatgc aggtttaaag 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600 acaaaggtta ccattttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg tggaacgatg gagacaacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa tcaggtgcca tggttccttc tgatgctgtt gacggtatct acggaacga gattttcgac 780 ttattagctt ctaacgccgg atgcggatct gcctcagata agttggcatg tttaagggga 840 gtctcttcag ataccttgga ggatgccacc aacaacacac caggattttt ggcctattct 900 tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagaggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgtctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gaatacacat catcttcaca gtctggaaac 1500 aatttgatga tgattaacgc cttaggtttg tacaccggta aagataactt taggacagct 1560 ggttacgacg ccttgttctc taacccacct tcatttttcg tatga 1605 <210> 15 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 2 (A249P) <400> 15 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac 60 gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 120 ccagtacctt actcaggttc attggacggt cagaaattca cctcttacgg tccatcttgt 180 atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg 240 gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt 300 aacgtcgtta ggcctcctgg aaccaaagcc ggtgctaatt tgcctgtcat gttatggatc 360 ttcggaggag gttttgaagt tggaggtaca tctacatttc cacctgccca gatgatcaca 420 aaatctatcg ccatgggaaa gcctattatc cacgtatcag tcaactatag ggtttcatct 480 tggggtttt tagctggaga cgaaatcaag gctgaaggat cagcaaatgc aggtttaaag 540 gaccagagat taggaatgca atgggttgcc gacaatatag cagcctttgg tggagaccct 600 acaaaggtta ccattttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg 660 tggaacgatg gagacaacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa 720 tcaggtgcca tggttccttc tgatccggtt gacggtatct acggaaacga gattttcgac 780 tttagctt ctaacgccgg atgcggatct gcctcagata agttggcatg tttaagggga 840 gtctcttcag ataccttgga ggatgccacc aacaacacac caggatttttt ggcctattct 900 tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagagggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgtctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gaatacacat catcttcaca gtctggaaac 1500 aatttgatga tgattaacgc cttaggtttg tacaccggta aagataactt taggacagct 1560 ggttacgacg ccttgttctc taacccacct tcatttttcg tatga 1605 <210> 16 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 3 (F259Y) <400> 16 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac 60 gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 120 ccagtacctt actcaggttc attggacggt cagaaattca cctcttacgg tccatcttgt 180 240. atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt aacgtcgtta ggcctcctgg aaccaaagcc ggtgctaatt tgcctgtcat gttatggatc 360 ttcggaggag gttttgaagt tggaggtaca tctacatttc cacctgccca gatgatcaca 420 aaatctatcg ccatgggaaa gcctattatc cacgtatcag tcaactatag ggtttcatct tggggttttt tagctggaga cgaaatcaag gctgaaggat cagcaaatgc aggtttaaag 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600 acaaaggtta ccattttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg tggaacgatg gagacaacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa tcaggtgcca tggttccttc tgatgctgtt gacggtatct acggaacga gatttacgac 780 ttattagctt ctaacgccgg atgcggatct gcctcagata agttggcatg tttaagggga 840 gtctcttcag ataccttgga ggatgccacc aacaacacac caggatttt ggcctattct tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagagggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gaatacacat catcttcaca gtctggaaac 1500 aatttgatga tgattaacgc cttaggttg tacaccggta aagataactt taggacagct 1560 ggttacgacg ccttgttctc taacccacct tcatttttcg tatga 1605 <210> 17 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 4 (S282P) <400> 17 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac 60 gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 120 ccagtacctt actcaggttc attggacggt cagaaattca cctcttacgg tccatcttgt 180 atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg 240 gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt 300 aacgtcgtta ggcctcctgg aaccaaagcc ggtgctaatt tgcctgtcat gttatggatc 360 ttcggaggag gttttgaagt tggaggtaca tctacatttc cacctgccca gatgatcaca 420 aaatctatcg ccatgggaaa gcctattatc cacgtatcag tcaactatag ggtttcatct 480 tggggttttt tagctggaga cgaaatcaag gctgaaggat cagcaaatgc aggtttaaag 540 gaccagagat taggaatgca atgggttgcc gacaatatag cagcctttgg tggagaccct 600 acaaaggtta ccattttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg 660 tggaacgatg gagacaacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa 720 tcaggtgcca tggttccttc tgatgctgtt gacggtatct acggaaacga gattttcgac 780 ttattagctt ctaacgccgg atgcggatct gcctcagata agttggcatg tttaagggga 840 gtcccgtcag ataccttgga ggatgccacc aacaacacac caggattttt ggcctattct 900 tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagagggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgtctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gaatacacat catcttcaca gtctggaaac 1500 aatttgatga tgattaacgc cttaggtttg tacaccggta aagataactt taggacagct 1560 ggttacgacg ccttgttctc taacccacct tcatttttcg tatga 1605 <210> 18 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 5 (S283Y) <400> 18 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac 60 gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 120 ccagtacctt actcaggttc attggacggt cagaaattca cctcttacgg tccatcttgt 180 atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg 240 gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt 300 aacgtcgtta ggctcctgg aaccaaagcc ggtgctaatt tgctgtcat gttatggatc 360 ttcggaggag gtttgaagt tggaggtaca tctacattc cacctgccca gatgatcaca 420 aaatctatcg ccatgggaaa gcctattatc cacgtatcag tcaactatag ggtttcatct 480 tggggttttt tagctggaga cgaatcaag gctgaaggat cagcaatgc aggtttaaag 540 gaccagagat taggaatgca atgggttgcc gaccatatag cagccttttgg tggaccct 600 aaaaggtta ccatttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg 660 tggaacgatg gagacacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa 720 tcaggtgcca tggttccttc tgatgctgtt gacggtatct acggaacga gattttcgac 780 attagctt ctaacgccgg atgcggatct gcttcagata agttggcatg tttaggga 840 gtctcttacg ataccttgga ggatgccacc aacacac caggatttt ggcctattct 900 tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagagggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgtctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gaatacacat catcttcaca gtctggaaac 1500 aatttgatga tgattaacgc cttaggtttg tacaccggta aagataactt taggacagct 1560 ggttacgacg ccttgttctc taacccacct tcatttttcg tatga 1605 <210> 19 <211> 1605 <212> DNA <213> Artificial Sequence <220> <223> Mutant Enzyme 6 (S300P) <400> 19 gcaccaactg caaccttagc aaacggagac acaatcactg gtttgaacgc cattatcaac gaagccttct tgggaatccc atttgccgaa ccacctgtcg gaaacttgag gttcaaggac 180. ccgtacctt actcaggttc attggacggt cagaattca cctcttacgg tccatcttgt 240. atgcaacaga atcctgaggg aacctatgag gagaacttgc caaaagcagc tttggatttg gtcatgcagt caaaagtctt cgaggccgtc tcaccatctt ctgaggactg tttgacaatt aacgtcgtta ggcctcctgg aaccaaagcc ggtgctaatt tgcctgtcat gttatggatc 360 ttcggaggag gttttgaagt tggaggtaca tctacatttc cacctgccca gatgatcaca 420 aaatctatcg ccatgggaaa gcctattatc cacgtatcag tcaactatag ggtttcatct tggggttttt tagctggaga cgaaatcaag gctgaaggat cagcaaatgc aggtttaaag 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600. 600 acaaaggtta ccattttcgg agaatctgct ggatctatgt cagtcatgtg ccacatattg tggaacgatg gagacaacac ctacaagggt aaaccattgt tcagagcagg tattatgcaa tcaggtgcca tggttccttc tgatgctgtt gacggtatct acggaaacga gattttcgac 780 ttattagctt ctaacgccgg atgcggatct gcctcagata agttggcatg tttaagggga 840 gtctcttcag ataccttgga ggatgccacc aacaacacac caggattttt ggcctatccg 900 tctttgagat tgtcatactt gcctagacca gacggagtca atattactga cgacatgtac 960 gcattagtca gagaggaaa gtacgcaaac atcccagtca taattggaga tcagaacgac 1020 gagggtacat tcttcggtac ctcatcattg aacgttacaa cagatgctca agcaagggag 1080 tatttcaaac aatcatttgt tcacgcatct gacgccgaaa tagacacttt aatgaccgcc 1140 tacccaggtg acataaccca gggttcacca ttcgatactg gtatcttaaa cgctttgaca 1200 cctcagttta aaaggatatc agctgttttg ggtgacttag gattcacatt agctagaaga 1260 tacttcttga atcactacac tggtggtaca aagtattctt tcttgtctaa gcaattatca 1320 ggtttgccag ttttaggaac cttccactct aatgacattg tcttccaaga ctacttgttg 1380 ggatctggat cattaatcta caataacgca ttcatcgcct ttgccacaga tttggaccct 1440 aacacagcag gattgttagt aaagtggcct gataccacat catctcaca gtctggaac 1500 aatttgatga tgattaacgc cttaggttg tacaccggta aagatactt taggacagct 1560 ggttacgacg ccttgttctc tacccacct tcattttcg tatga 1605 <210> 20 <211> 45 <212> DNA <213> sweet and sour <400> 20 atggagctcg ctcttgcgct cctgctcatt gcctcggtgg ctgct 45 <210> 21 <211> 15 <212> PRT <213> sweet and sour <400> 21 Met Glu Leo Wing Leo Wing Leo Ser Leu Ile Wing Ser Val Wing Wing 1 5 10 15 <210> 22 <211> 549 <212> PRT <213> sweet and sour <400> 22 Met Glu Leu Wing Leo Wing Leu Ser Leu Ile Wing Ser Val Wing Wing Wing 1 5 10 15 Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn Ala 20 25 30 Ile Ile Asn Glu Ala Phe Leu Gly Pro Phe Ala Glu Pro Pro Val 35 40 45 Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu Asp 50 55 60 Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn Pro 65 70 75 80 Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Ala Ala Leu Asp Leu Val 85 90 95 Met Gln Ser Lys Val Phe Glu Ala Val Ser Pro Ser Ser Glu Asp Cys 100 105 110 Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala Asn 115 120 125 Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Val Gly Gly 130 135 140 Thr Ser Thr Phe Pro Pro Ala Gln Met Ile Thr Lys Ser Ile Ala Met 145 150 155 160 Gly Lys Pro Ile Ile His Val Ser Val Asn Tyr Arg Val Ser Ser Trp 165 170 175 Gly Phe Leu Ala Gly Asp Glu Ile Lys Ala Glu Gly Ser Ala Asn Ala 180 185 190 Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn Ile 195 200 205 Ala Ala Phe Gly Gly Asp Pro Thr Lys Val Thr Ile Phe Gly Glu Ser 210 215 220 Ala Gly Ser Met Ser Val Met Cys His Ile Leu Trp Asn Asp Gly Asp 225 230 235 240 Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln Ser 245 250 255 Gly Ala Met Val Pro Ser Asp Ala Val Asp Gly Ile Tyr Gly Asn Glu 260 265 270 Ile Phe Asp Leu Leu Ala Ser Asn Ala Gly Cys Gly Ser Ala Ser Asp 275 280 285 Lys Leu Ala Cys Leu Arg Gly Val Ser Ser Asp Thr Leu Glu Asp Ala 290 295 300 Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu Ser 305 310 315 320 Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Met Tyr Ala 325 330 335 Leu Val Arg Glu Gly Lys Tyr Ala Asn Ile Pro Val Ile Ile Gly Asp 340 345 350 Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Ser Ser Leu Asn Val Thr 355 360 365 Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Val His Ala 370 375 380 Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp Ile 385 390 395 400 Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr Pro 405 410 415 Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Gly Phe Thr Leu 420 425 430 Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr Ser 435 440 445 Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe His 450 455 460 Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser Leu 465 470 475 480 Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro Asn 485 490 495 Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Ser Gln 500 505 510 Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr Gly 515 520 525 Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn Pro 530 535 540 Pro Ser Phe Phe Val 545 <210> 23 <211> 1650 <212> DNA <213> Candida cylindracea <400> 23 atggagctcg ctcttgcgct cctgctcatt gcctcggtgg ctgctgcccc caccgccacg 60 ctcgccaacg gcgacaccat caccggtctc aacgccatca tcaacgaggc gttcctcggc 120 attccctttg ccgagccgcc ggtgggcaac ctccgcttca aggaccccgt gccgtactcc 180 ggctcgctcg atggccagaa gttcacgctg tacggcccgc tgtgcatgca gcagaacccc 240 gagggcacct acgaggagaa cctccccaag gcagcgctcg acttggtgat gcagtccaag 300 gtgtttgagg cggtgctgcc gctgagcgag gactgtctca ccatcaacgt ggtgcggccg 360 ccgggcacca aggcgggtgc caacctcccg gtgatgctct ggatctttgg cggcgggttt 420 gaggtgggtg gcaccagcac cttccctccc gcccagatga tcaccaagag cattgccatg 480 ggcaagccca tcatccacgt gagcgtcaac taccgcgtgt cgtcgtgggg gttcttggct 540 ggcgacgaga tcaaggccga gggcagtgcc aacgccggtt tgaaggacca gcgcttgggc 600 atgcagtggg tggcggacaa cattgcggcg tttggcggcg acccgaccaa ggtgaccatc 660 tttggcgagc tggcgggcag catgtcggtc atgtgccaca ttctctggaa cgacggcgac 720 aacacgtaca agggcaagcc gctcttccgc gcgggcatca tgcagctggg ggccatggtg 780 ccgctggacg ccgtggacgg catctacggc aacgagatct ttgacctctt ggcgtcgaac 840 gcgggctgcg gcagcgccag cgacaagctt gcgtgcttgc gcggtgtgct gagcgacacg 900 ttggaggacg ccaccaacaa cacccctggg ttcttggcgt actcctcgtt gcggttgctg 960 tacctccccc ggcccgacgg cgtgaacatc accgacgaca tgtacgcctt ggtgcgcgag 1020 ggcaagtatg ccaacatccc tgtgatcatc ggcgaccaga acgacgaggg caccttcttt 1080 ggcaccctgc tgttgaacgt gaccacggat gcccaggccc gcgagtactt caagcagctg 1140 tttgtccacg ccagcgacgc ggagatcgac acgttgatga cggcgtaccc cggcgacatc 1200 acccagggcc tgccgttcga cacgggtatt ctcaacgccc tcaccccgca gttcaagaga 1260 atcctggcgg tgctcggcga ccttggcttt acgcttgctc gtcgctactt cctcaaccac 1320 tacaccggcg gcaccaagta ctcattcctc ctgaagcagc tcctgggctt gccggtgctc 1380 ggaacgttcc actccaacga cattgtcttc caggactact tgttgggcag cggctcgctc 1440 atctacaaca acgcgttcat tgcgtttgcc acggacttgg accccaacac cgcggggttg 1500 ttggtgaagt ggcccgagta caccagcagc ctgcagctgg gcaacaactt gatgatgatc 1560 aacgccttgg gcttgtacac cggcaaggac aacttccgca ccgccggcta cgacgcgttg 1620 ttctccaacc cgccgctgtt ctttgtgtga 1650 <210> 24 <211> 534 <212> PRT <213> Candida cylindracea <400> 24 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Val Asn Glu Lys Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Thr Leu Arg Phe Lys Pro Pro Val Pro Tyr Ser Ala Ser Leu 35 40 45 Asn Gly Gln Gln Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Met Asn 50 55 60 Pro Met Gly Ser Phe Glu Asp Thr Leu Pro Lys Asn Ala Arg His Leu 65 70 75 80 Val Leu Gln Ser Lys Ile Phe Gln Val Val Leu Pro Asn Asp Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Ile Arg Pro Pro Gly Thr Arg Ala Ser Ala 100 105 110 Gly Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Leu Gly 115 120 125 Gly Ser Ser Leu Phe Pro Gly Asp Gln Met Val Ala Lys Ser Val Leu 130 135 140 Met Gly Lys Pro Val Ile His Val Ser Met Asn Tyr Arg Val Ala Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Pro Asp Ile Gln Asn Glu Gly Ser Gly Asn 165 170 175 Ala Gly Leu His Asp Gln Arg Leu Ala Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Tyr Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Thr Phe Val His Leu Val Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Asn Gly Lys Pro Leu Phe Arg Ala Ala Ile Met Gln 225 230 235 240 Ser Gly Cys Met Val Pro Ser Asp Pro Val Asp Gly Thr Tyr Gly Thr 245 250 255 Glu Ile Tyr Asn Gln Val Val Ala Ser Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Gly Leu Ser Gln Asp Thr Leu Tyr Gln 275 280 285 Ala Thr Ser Asp Thr Pro Gly Val Leu Ala Tyr Pro Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Thr Phe Ile Thr Asp Asp Met Tyr 305 310 315 320 Ala Leu Val Arg Asp Gly Lys Tyr Ala His Val Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Leu Phe Gly Leu Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Ala Tyr Phe Lys Gln Ser Phe Ile His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Ala Ala Tyr Thr Ser Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Phe Asn Ala Ile Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Leu Leu Gly Asp Leu Ala Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn Tyr Tyr Gln Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Gly Asn Asp Ile Ile Trp Gln Asp Tyr Leu Val Gly Ser Gly Ser 450 455 460 Val Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Asn Asp Leu Asp Pro 465 470 475 480 Asn Lys Ala Gly Leu Trp Thr Asn Trp Pro Thr Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Gln Ile Asn Gly Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Pro Asp Ala Tyr Ser Ala Leu Phe Ser Asn 515 520 525 Pro Pro Ser Phe Phe Val 530 <210> 25 <211> 534 <212> PRT <213> Candida cylindracea <400> 25 Ala Pro Thr Ala Lys Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu 35 40 45 Asn Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Phe Glu Glu Asn Leu Gly Lys Thr Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Gln Ala Val Leu Pro Gln Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Ile Gly 115 120 125 Ser Pro Thr Ile Phe Pro Pro Ala Gln Met Val Thr Lys Ser Val Leu 130 135 140 Met Gly Lys Pro Ile Ile His Val Ala Val Asn Tyr Arg Val Ala Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Asp Asp Ile Lys Ala Glu Gly Ser Gly Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Leu Cys His Leu Ile Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Pro Val Asp Gly Thr Tyr Gly Asn 245 250 255 Glu Ile Tyr Asp Leu Phe Val Ser Ser Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Ser Ala Ser Ser Asp Thr Leu Leu Asp 275 280 285 Ala Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Lys Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Lys Leu Val Arg Asp Gly Lys Tyr Ala Ser Val Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Ile Phe Gly Leu Ser Ser Leu Asn Val 340 345 350 Thr Thr Asn Ala Gln Ala Arg Ala Tyr Phe Lys Gln Ser Phe Ile His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Ala Ala Tyr Pro Gln Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Phe Asn Ala Ile Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Ala Phe Ile 405 410 415 His Ala Arg Arg Tyr Phe Leu Asn His Phe Gln Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Ile Met Gly Thr Phe 435 440 445 His Ala Asn Asp Ile Val Trp Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Val Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Asn Trp Pro Lys Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Met Thr Asn 515 520 525 Pro Ser Ser Phe Phe Val 530 <210> 26 <211> 534 <212> PRT <213> Candida cylindracea <400> 26 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Gln Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Pro Pro Val Pro Tyr Ser Ala Ser Leu 35 40 45 Asn Gly Gln Lys Phe Thr Ser Tyr Gly Pro Ser Cys Met Gln Met Asn 50 55 60 Pro Leu Gly Asn Trp Asp Ser Ser Leu Pro Lys Ala Ala Ile Asn Ser 65 70 75 80 Leu Met Gln Ser Lys Leu Phe Gln Ala Val Leu Pro Asn Gly Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Ser Gly Thr Lys Pro Gly Ala 100 105 110 Asn Leu Pro Val Met Val Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Ser Ser Leu Phe Pro Pro Ala Gln Met Ile Thr Ala Ser Val Leu 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Met Asn Tyr Arg Val Ala Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Pro Asp Ile Lys Ala Glu Gly Ser Gly Asn 165 170 175 Ala Gly Leu His Asp Gln Arg Leu Gly Leu Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Met Cys Gln Leu Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Asn Gly Lys Pro Leu Phe Arg Ala Ala Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Pro Val Asp Gly Pro Tyr Gly Thr 245 250 255 Gln Ile Tyr Asp Gln Val Val Ala Ser Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Ser Ile Ser Asn Asp Lys Leu Phe Gln 275 280 285 Ala Thr Ser Asp Thr Pro Gly Ala Leu Ala Tyr Pro Ser Leu Arg Leu 290 295 300 Ser Phe Leu Pro Arg Pro Asp Gly Thr Phe Ile Thr Asp Asp Met Phe 305 310 315 320 Lys Leu Val Arg Asp Gly Lys Cys Ala Asn Val Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Val Phe Ala Leu Ser Ser Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Gln Tyr Phe Lys Glu Ser Phe Ile His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Ala Ala Tyr Pro Ser Asp 370 375 380 Ile Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Phe Asn Ala Ile Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Ala Ala Val Leu Gly Asp Leu Ala Phe Thr 405 410 415 Leu Pro Arg Arg Tyr Phe Leu Asn His Phe Gln Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Ile Gly Thr His 435 440 445 His Ala Asn Asp Ile Val Trp Gln Asp Phe Leu Val Ser His Ser Ser 450 455 460 Ala Val Tyr Asn Asn Ala Phe Ile Ala Phe Ala Asn Asp Leu Asp Pro 465 470 475 480 Asn Lys Ala Gly Leu Leu Val Asn Trp Pro Lys Tyr Thr Ser Ser Ser 485 490 495 Gln Ser Gly Asn Asn Leu Leu Gln Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Thr Asn 515 520 525 Pro Ser Ser Phe Phe Val 530 <210> 27 <211> 534 <212> PRT <213> Candida cylindracea <400> 27 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn 1 5 10 15 Ala Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Arg Gly Ser Leu 35 40 45 Asn Gly Gln Ser Phe Thr Ala Tyr Gly Pro Ser Cys Met Gln Gln Asn 50 55 60 Pro Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Val Ala Leu Asp Leu 65 70 75 80 Val Met Gln Ser Lys Val Phe Gln Ala Val Leu Pro Asn Ser Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala 100 105 110 Asn Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Ile Gly 115 120 125 Ser Pro Thr Ile Phe Pro Pro Ala Gln Met Val Ser Lys Ser Val Leu 130 135 140 Met Gly Lys Pro Ile Ile His Val Ala Val Asn Tyr Arg Leu Ala Ser 145 150 155 160 Phe Gly Phe Leu Ala Gly Pro Asp Ile Lys Ala Glu Gly Ser Ser Asn 165 170 175 Ala Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu 195 200 205 Ser Ala Gly Ser Met Ser Val Leu Cys His Leu Leu Trp Asn Gly Gly 210 215 220 Asp Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln 225 230 235 240 Ser Gly Ala Met Val Pro Ser Asp Pro Val Asp Gly Thr Tyr Gly Thr 245 250 255 Gln Ile Tyr Asp Thr Leu Val Ala Ser Thr Gly Cys Ser Ser Ala Ser 260 265 270 Asn Lys Leu Ala Cys Leu Arg Gly Leu Ser Thr Gln Ala Leu Leu Asp 275 280 285 Ala Thr Asn Asp Thr Pro Gly Phe Leu Ser Tyr Thr Ser Leu Arg Leu 290 295 300 Ser Tyr Leu Pro Arg Pro Asp Gly Ala Asn Ile Thr Asp Asp Met Tyr 305 310 315 320 Lys Leu Val Arg Asp Gly Lys Tyr Ala Ser Val Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Phe Leu Phe Gly Leu Ser Ser Leu Asn Thr 340 345 350 Thr Thr Glu Ala Asp Ala Glu Ala Tyr Leu Arg Lys Ser Phe Ile His 355 360 365 Ala Thr Asp Ala Asp Ile Thr Ala Leu Lys Ala Ala Tyr Pro Ser Asp 370 375 380 Val Thr Gln Gly Ser Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Leu Lys Arg Ile Asn Ala Val Leu Gly Asp Leu Thr Phe Thr 405 410 415 Leu Ser Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Pro Lys Tyr 420 425 430 Ser Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Ile Leu Gly Thr Phe 435 440 445 His Ala Asn Asp Ile Val Trp Gln His Phe Leu Leu Gly Ser Gly Ser 450 455 460 Val Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Ser Val Gln Trp Pro Lys Ser Thr Ser Ser Ser 485 490 495 Gln Ala Gly Asp Asn Leu Met Gln Ile Ser Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asn Ala Leu Phe Ala Asp 515 520 525 Pro Ser His Phe Phe Val 530 <210> 28 <211> 549 <212> PRT <213> Candida rugosa <400> 28 Met Glu Leu Ala Leu Ala Leu Ser Leu Ile Ala Ser Val Ala Ala Ala 1 5 10 15 Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn Ala 20 25 30 Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro Val 35 40 45 Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Arg Gly Ser Leu Asn 50 55 60 Gly Gln Ser Phe Thr Ala Tyr Gly Pro Ser Cys Met Gln Gln Asn Pro 65 70 75 80 Glu Gly Thr Tyr Glu Glu Asn Leu Pro Lys Val Ala Leu Asp Leu Val 85 90 95 Met Gln Ser Lys Val Phe Gln Ala Val Leu Ser Asn Ser Glu Asp Cys 100 105 110 Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala Asn 115 120 125 Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Ile Gly Ser 130 135 140 Pro Thr Ile Phe Pro Pro Ala Gln Met Val Ser Lys Ser Val Leu Met 145 150 155 160 Gly Lys Pro Ile Ile His Val Ala Val Asn Tyr Arg Leu Ala Ser Phe 165 170 175 Gly Phe Leu Ala Gly Pro Asp Ile Lys Ala Glu Gly Ser Ser Asn Ala 180 185 190 Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn Ile 195 200 205 Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu Ser 210 215 220 Ala Gly Ser Met Ser Val Leu Cys His Leu Leu Trp Asn Gly Gly Asp 225 230 235 240 Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln Ser 245 250 255 Gly Ala Met Val Pro Ser Asp Pro Val Asp Gly Thr Tyr Gly Thr Gln 260 265 270 Ile Tyr Asp Thr Leu Val Ala Ser Thr Gly Cys Ser Ser Ala Ser Asn 275 280 285 Lys Leu Ala Cys Leu Arg Gly Leu Ser Thr Gln Ala Leu Leu Asp Ala 290 295 300 Thr Asn Asp Thr Pro Gly Phe Leu Ala Phe Ser Ser Leu Arg Leu Ser 305 310 315 320 Tyr Leu Pro Arg Pro Asp Gly Val Asn Ile Thr Asp Asp Phe Tyr Ala 325 330 335 Leu Val Arg Asn Gly Lys Tyr Ala His Val Pro Val Ile Ile Gly Asp 340 345 350 Gln Asn Asp Glu Gly Thr Ile Phe Gly Leu Ser Ser Leu Asn Val Thr 355 360 365 Thr Asn Ala Gln Ala Arg Glu Tyr Phe Lys Gln Ser Phe Ile His Ala 370 375 380 Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gln Asp Ile 385 390 395 400 Thr Gln Gly Ser Pro Phe Asp Thr Gly Val Leu Asn Ala Leu Thr Pro 405 410 415 Gln Phe Lys Arg Ile Ser Ala Val Leu Gly Asp Leu Ala Phe Thr Leu 420 425 430 Ala Arg Arg Tyr Phe Leu Asn Tyr Tyr Gln Gly Gly Thr Lys Tyr Ser 435 440 445 Phe Leu Ser Lys Gln Leu Ser Gly Leu Pro Val Leu Gly Thr Phe His 450 455 460 Ser Asn Asp Leu Thr Phe Gln Asn Asp Leu Leu Gly Ser Gly Ser Leu 465 470 475 480 Ile Tyr Asp Asn Ala Phe Ile Ala Phe Val Asn Asp Leu Asp Pro Asn 485 490 495 Lys Ala Gly Leu Leu Val Asn Trp Pro Thr Tyr Thr Ser Ser Ser Gln 500 505 510 Ser Gly Asn Asn Met Met Met Ile Asn Ala Leu Gly Leu Tyr Thr Gly 515 520 525 Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ala Asn Pro 530 535 540 Pro Ser Phe Phe Val 545 <210> 29 <211> 549 <212> PRT <213> Candida cylindracea <400> 29 Met Lys Leu Ala Leu Ala Leu Leu Leu Ile Ala Ser Val Ala Ala Ala 1 5 10 15 Pro Thr Ala Lys Leu Ala Asn Gly Asp Thr Ile Thr Gly Leu Asn Ala 20 25 30 Ile Ile Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro Val 35 40 45 Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Gly Ser Leu Asn 50 55 60 Gly Gln Lys Phe Thr Leu Tyr Gly Pro Leu Cys Met Gln Gln Asn Pro 65 70 75 80 Glu Gly Thr Phe Glu Glu Asn Leu Gly Lys Thr Ala Leu Asp Leu Val 85 90 95 Met Gln Ser Lys Val Phe Gln Ala Val Leu Pro Gln Ser Glu Asp Cys 100 105 110 Leu Thr Ile Asn Val Val Arg Pro Pro Gly Thr Lys Ala Gly Ala Asn 115 120 125 Leu Pro Val Met Leu Trp Ile Phe Gly Gly Gly Phe Glu Ile Gly Ser 130 135 140 Pro Thr Ile Phe Pro Pro Ala Gln Met Val Thr Lys Ser Val Leu Met 145 150 155 160 Gly Lys Pro Ile Ile His Val Ala Val Asn Tyr Arg Val Ala Ser Trp 165 170 175 Gly Phe Leu Ala Gly Asp Asp Ile Lys Ala Glu Gly Ser Gly Asn Ala 180 185 190 Gly Leu Lys Asp Gln Arg Leu Gly Met Gln Trp Val Ala Asp Asn Ile 195 200 205 Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu Leu 210 215 220 Ala Gly Ser Met Ser Val Leu Cys His Leu Ile Trp Asn Asp Gly Asp 225 230 235 240 Asn Thr Tyr Lys Gly Lys Pro Leu Phe Arg Ala Gly Ile Met Gln Leu 245 250 255 Gly Ala Met Val Pro Leu Asp Pro Val Asp Gly Thr Tyr Gly Asn Glu 260 265 270 Ile Tyr Asp Leu Phe Val Ser Ser Ala Gly Cys Gly Ser Ala Ser Asp 275 280 285 Lys Leu Ala Cys Leu Arg Ser Ala Leu Ser Asp Thr Leu Leu Asp Ala 290 295 300 Thr Asn Asn Thr Pro Gly Phe Leu Ala Tyr Ser Ser Leu Arg Leu Leu 305 310 315 320 Tyr Leu Pro Arg Pro Asp Gly Lys Asn Ile Thr Asp Asp Met Tyr Lys 325 330 335 Leu Val Arg Asp Gly Lys Tyr Ala Ser Val Pro Val Ile Ile Gly Asp 340 345 350 Gln Asn Asp Glu Gly Thr Ile Phe Gly Leu Leu Leu Leu Asn Val Thr 355 360 365 Thr Asn Ala Gln Ala Arg Ala Tyr Phe Lys Gln Leu Phe Ile His Ala 370 375 380 Ser Asp Ala Glu Ile Asp Thr Leu Met Ala Ala Tyr Pro Gln Asp Ile 385 390 395 400 Thr Gln Gly Leu Pro Phe Asp Thr Gly Ile Phe Asn Ala Ile Thr Pro 405 410 415 Gln Phe Lys Arg Ile Leu Ala Val Leu Gly Asp Leu Ala Phe Ile His 420 425 430 Ala Arg Arg Tyr Phe Leu Asn His Phe Gln Gly Gly Thr Lys Tyr Ser 435 440 445 Phe Leu Leu Lys Gln Leu Leu Gly Leu Pro Ile Met Gly Thr Phe His 450 455 460 Ala Asn Asp Ile Val Trp Gln Asp Tyr Leu Leu Gly Ser Gly Ser Val 465 470 475 480 Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro Asn 485 490 495 Thr Ala Gly Leu Leu Val Asn Trp Pro Lys Tyr Thr Ser Ser Leu Gln 500 505 510 Leu Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr Gly 515 520 525 Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Met Thr Asn Pro 530 535 540 Leo Leo Phe Phe Val 545 <210> 30 <211> 534 <212> PRT <213> AC-IITM <400> 30 Ala Pro Thr Ala Thr Leu Ala Asn Gly Asp Thr Ile Thr Gly Val Asn 1 5 10 15 Lys Ile Val Asn Glu Ala Phe Leu Gly Ile Pro Phe Ala Glu Pro Pro 20 25 30 Val Gly Asn Leu Arg Phe Lys Asp Pro Val Pro Tyr Ser Arg Ser Leu 35 40 45 Asn Gly Gln Lys Phe Thr Leu Asn Gly Pro Leu Cys Met Gln Met Asn 50 55 60 Pro Leu Gly Asn Trp Asp Ser Ser Leu Pro Lys Ala Ala Ile Asn Leu 65 70 75 80 Leu Met Gln Ser Lys Leu Phe Gln Ala Val Leu Pro Asn Gly Glu Asp 85 90 95 Cys Leu Thr Ile Asn Val Val Arg Pro Leu Gly Thr Lys Pro Gly Ala 100 105 110 Asn Leu Pro Val Met Val Trp Ile Phe Gly Gly Gly Phe Glu Val Gly 115 120 125 Gly Ser Ser Leu Phe Pro Pro Ala Gln Met Ile Thr Ala Ser Val Leu 130 135 140 Met Gly Lys Pro Ile Ile His Val Ser Met Asn Tyr Arg Val Ala Ser 145 150 155 160 Trp Gly Phe Leu Ala Gly Pro Asp Ile Lys Ala Glu Gly Ser Gly Asn 165 170 175 Ala Gly Leu His Asp Gln Arg Leu Gly Leu Gln Trp Val Ala Asp Asn 180 185 190 Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Thr Ile Phe Gly Glu 195 200 205 Leu Ala Gly Ser Met Ser Val Met Cys Gln Leu Leu Trp Asn Asp Gly 210 215 220 Asp Asn Thr Tyr Asn Gly Lys Pro Leu Phe Arg Ala Ala Ile Met Gln 225 230 235 240 Leu Gly Ala Met Val Pro Leu Asp Pro Val Asp Gly Pro Tyr Gly Thr 245 250 255 Gln Ile Tyr Asp Gln Val Val Ala Ser Ala Gly Cys Gly Ser Ala Ser 260 265 270 Asp Lys Leu Ala Cys Leu Arg Ser Ile Leu Asn Asp Lys Leu Phe Gln 275 280 285 Ala Thr Ser Asp Thr Pro Gly Ala Leu Ala Tyr Pro Ser Leu Arg Leu 290 295 300 Leu Phe Leu Pro Arg Pro Asp Gly Thr Phe Ile Thr Asp Asp Met Phe 305 310 315 320 Lys Leu Val Arg Asp Gly Lys Cys Ala Asn Ile Pro Val Ile Ile Gly 325 330 335 Asp Gln Asn Asp Glu Gly Thr Phe Phe Gly Thr Leu Leu Leu Asn Val 340 345 350 Thr Thr Asp Ala Gln Ala Arg Glu Tyr Phe Lys Gln Leu Phe Val His 355 360 365 Ala Ser Asp Ala Glu Ile Asp Thr Leu Met Thr Ala Tyr Pro Gly Asp 370 375 380 Ile Thr Gln Gly Leu Pro Phe Asp Thr Gly Ile Leu Asn Ala Leu Thr 385 390 395 400 Pro Gln Phe Lys Arg Ile Leu Ala Val Leu Gly Asp Leu Gly Phe Thr 405 410 415 Leu Ala Arg Arg Tyr Phe Leu Asn His Tyr Thr Gly Gly Thr Lys Tyr 420 425 430 Ser Phe Leu Leu Lys Gln Leu Leu Gly Leu Pro Val Leu Gly Thr Phe 435 440 445 His Ser Asn Asp Ile Val Phe Gln Asp Tyr Leu Leu Gly Ser Gly Ser 450 455 460 Leu Ile Tyr Asn Asn Ala Phe Ile Ala Phe Ala Thr Asp Leu Asp Pro 465 470 475 480 Asn Thr Ala Gly Leu Leu Val Lys Trp Pro Glu Tyr Thr Ser Ser Leu 485 490 495 Gln Leu Gly Asn Asn Leu Met Met Ile Asn Ala Leu Gly Leu Tyr Thr 500 505 510 Gly Lys Asp Asn Phe Arg Thr Ala Gly Tyr Asp Ala Leu Phe Ser Asn 515 520 525 Pro Leo Leo Phe Phe Val 530

Claims

1. A modified lipase having an amino acid sequence of SEQ ID NO: 2, wherein the modified lipase has improved reactivity at 55°C to 65°C and / or improved stability at 45°C to 55°C compared to the lipase having the amino acid sequence of SEQ ID NO:

1.

2. The modified lipase according to claim 1, wherein The amino acid substitution contained in the amino acid sequence of the modified lipase is T130C-S153C, and the reactivity at 55°C to 65°C is improved.

3. A gene encoding the modified lipase according to claim 1 or 2.

4. The gene according to claim 3, wherein Contains the base sequence of sequence number 8 or 14.

5. A recombinant DNA comprising the gene according to claim 3 or 4.

6. A microorganism comprising the recombinant DNA according to claim 5.

7. The microorganism according to claim 6, wherein The host is Escherichia coli, Candida columnaris, Aspergillus oryzae, Bacillus subtilis or Pichia pastoris.

8. An enzyme preparation comprising the modified lipase according to claim 1 or 2.

9. A method for decomposing fats and oils, characterized in that: The enzyme according to claim 1 or 2 or the enzyme preparation according to claim 8 is allowed to act on fats and oils to carry out an enzyme reaction.

10. The decomposition method according to claim 9, wherein: The enzyme reaction was carried out at 30°C to 60°C.

11. A method for preparing a modified lipase, comprising the following steps (I) to (III): (I) preparing a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2; (II) a step of expressing the nucleic acid, and (III) A step of recovering the expression product.